Rifkin, Robert M. http://orcid.org/0000-0003-3141-1518
Girnius, Saulius K.
Noga, Stephen J.
Birhiray, Ruemu E.
Kambhampati, Suman
Manda, Sudhir
Lyons, Roger M.
Yimer, Habte A.
Cherepanov, Dasha
Lloyd, Eric
Whidden, Presley
Richter, Joshua http://orcid.org/0000-0002-0274-0585
Funding for this research was provided by:
Takeda Development Center Americas, Inc.
Article History
Received: 16 May 2023
Revised: 22 August 2023
Accepted: 24 August 2023
First Online: 19 September 2023
Competing interests
: RMR: Member of board of directors/advisory committee: Amgen, Bristol Myers Squibb (Celgene), Coherus, Fresenius-Kabi, Sanofi, Takeda, and Karyopharm; Current employee and equity holder: McKesson. SKG: Honoraria: BMS, Genentech, and GSK; Speakers bureau: BMS, Celgene, GSK, Takeda, and Beigene; Member of board of directors/advisory committee: Takeda. SJN: Current employee: Takeda. REB: Consultancy: Alexion, AbbVie, Novartis, Janssen, Pharmacyclics, and Puma; Honoraria: AbbVie, Novartis, Bayer, Seattle Genetics, Coheris, Kyte Pharma, Celgene, Helsin, and Amgen; Research funding: Puma, Takeda, and Incyte; Speakers bureau: Novartis, Janssen, Pharmacyclics, Puma, Takeda, Incyte, Amgen, Pfizer, BMS, Tessaro, AstraZeneca, Genomic Health, Sanofi, Clovis, Exelexis, and Lilly. SK: nothing to disclose. S.M.: Honoraria: Morphosys; Current equity holder: Genmab. RML: nothing to disclose. HAY: Speakers bureau: Karyopharm, AstraZeneca, Janssen, Beigene, GSK, Sanofi, Amgen, Pharmacyclics, and Takeda; Current stockholder: Karyopharm; Current employee: Texas Oncology. DC: Current employee: Takeda; Ownership of stock/shares with Takeda. EL: Current employee: Takeda. PW: Current employee: Takeda. JR: Consulting fees from Takeda and BMS/Celgene.